Quality of life and employment status are correlated with antiepileptic monotherapy versus polytherapy and not with use of "newer" versus "classic" drugs: Results of the "Compliant 2006" survey in 907 patients

Epilepsy and Behavior

Volumn 19, Issue 4, 2010, Pages 618-622

  Haag, A ^a   Strzelczyk, A ^a   Bauer, S ^a   Kuhne S ^b   Hamer, H M ^a   Rosenow, F ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Employment; Epilepsy drug therapy; Monotherapy; Polytherapy; Quality of life

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; EMPLOYMENT STATUS; EPILEPSY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; QUALITY OF LIFE; SEIZURE;

ADULT; AGED; ANTICONVULSANTS; DRUG THERAPY, COMBINATION; EMPLOYMENT; EPILEPSY; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; QUALITY OF LIFE; REGRESSION ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649946369     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.09.037     Document Type: Article

References (24)

1. Forsgren L., Beghi E., Oun A., Sillanpaa M. The epidemiology of epilepsy in Europe: a systematic review. Eur J Neurol 2005, 12:245-253.
2. Steinhoff B.J., Hirsch E., Mutani R., Nakken K.O. The ideal characteristics of antiepileptic therapy: an overview of old and new AEDs. Acta Neurol Scand 2003, 107:87-95.
3. Azar N.J., Abou-Khalil B.W. Considerations in the choice of an antiepileptic drug in the treatment of epilepsy. Semin Neurol 2008, 28:305-316.
4. Strzelczyk A., Reese J.P., Dodel R., Hamer H.M. Cost of epilepsy: a systematic review. Pharmacoeconomics 2008, 26:463-476.
5. Bauer S., Hamer H.M. Stellenwert neuer Antiepileptika in der Praxis. Neurol Psychiatr 2008, 9:45-48.
6. Legros B., Boon P., Dejonghe P., Sadzot B., van Rijckevorsel K., Schmedding E. Opinion of Belgian neurologists on antiepileptic drugs. Acta Neurol Scand 2007, 115:97-103. for the Belgian Study on Epilepsy Treatment (BESET).
7. Wilby J., Kainth A., Hawkins N., et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005, 9:i-iv.
8. Marson A.G., Appleton R., Baker G.A., et al. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. Health Technol Assess 2007, 11:iii-x. for the SANAD Trial, 1.
9. Pfäfflin M., May T., Stefan H., Adelmeier U. Epilepsiebedingte Beeinträchtigungen im täglichen Leben und in der Erwerbstätigkeit: Querschnittsstudie an Patienten niedergelassener Ärzte. Neurol Rehabil 2000, 6:140-148.
10. Fisher R.S., Vickrey B.G., Gibson P., et al. The impact of epilepsy from the patient's perspective I. Descriptions and subjective perceptions. Epilepsy Res 2000, 41:39-51.
11. Jacoby A., Gorry J., Baker G.A. Employers' attitudes to employment of people with epilepsy: still the same old story?. Epilepsia 2005, 46:1978-1987.
12. Hamer H.M., Spottke A., Aletsee C., et al. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006, 47:2165-2172.
13. Fisher R.S., Vickrey B.G., Gibson P., et al. The impact of epilepsy from the patient's perspective: II. Views about therapy and health care. Epilepsy Res 2000, 41:53-61.
14. Toledano R., Gil-Nagel A. Adverse effects of antiepileptic drugs. Semin Neurol 2008, 28:317-327.
15. Faught E., Duh M.S., Weiner J.R., Guerin A., Cunnington M.C. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology 2008, 71:1572-1578.
16. Davis K.L., Candrilli S.D., Edin H.M. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 2008, 49:446-454.
17. Paschal A.M., Hawley S.R., St Romain T., Ablah E. Measures of adherence to epilepsy treatment: review of present practices and recommendations for future directions. Epilepsia 2008, 49:1115-1122.
18. Specht U. Compliance with antiepileptic drugs. Nervenarzt 2008, 79:662-668.
19. Bishop M. Determinants of employment status among a community-based sample of people with epilepsy: lmplications for rehabilitation interventions. Rehabil Couns Bull 2004, 47:112-121.
20. Theodore W.H., Spencer S.S., Wiebe S., et al. Epilepsy in North America: a report prepared under the auspices of the Global Campaign Against Epilepsy, the International Bureau for Epilepsy, the International League Against Epilepsy, and the World Health Organization. Epilepsia 2006, 47:1700-1722.
21. Rattya J., Turkka J., Pakarinen A.J., et al. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001, 56:31-36.
22. Sachdeo R., Sathyan R.R. Amelioration of erectile dysfunction following a switch from carbamazepine to oxcarbazepine: recent clinical experience. Curr Med Res Opin 2005, 21:1065-1068.
23. Tracy J.I., Dechant V., Sperling M.R., Cho R., Glosser D. The association of mood with quality of life ratings in epilepsy. Neurology 2007, 68:1101-1107.
24. Canuet L., Ishii R., Iwase M., et al. Factors associated with impaired quality of life in younger and older adults with epilepsy. Epilepsy Res 2009, 83:58-65.